Incensole Acetate
Based on 1 Customer Validation
Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs.
For research use only. We do not sell to patients.
- Purity: 99.08%
- CAS No.: 34701-53-6
- Formula: C22H36O3
- Molecular Weight:348.52
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Apoptosis Compound Library
HY-L003
-
Natural Product Library
HY-L021
-
Terpenoids Library
HY-L056
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Neuroprotective Compound Library
HY-L070
-
Plant-Sourced Natural Product Library
HY-L115
-
Cell Death Library
HY-L162
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Mass Spectrometry Natural Product Library
HY-L262
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
1.4 μM
Compound: 1b
|
Activation of rat TRPV3 overexpressed in HEK293 cells assessed as increase in 2-aminoethoxydiphenyl borate-induced intracellular calcium concentration by Fluo-4AM dye-based spectrofluorometry
Activation of rat TRPV3 overexpressed in HEK293 cells assessed as increase in 2-aminoethoxydiphenyl borate-induced intracellular calcium concentration by Fluo-4AM dye-based spectrofluorometry
|
[PMID: 27352042] |
| HEK293 | EC50 |
16 μM
Compound: 1b
|
Agonist activity at mouse YFP-tagged TRPV3 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-2-AM dye based microscopic analysis
Agonist activity at mouse YFP-tagged TRPV3 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-2-AM dye based microscopic analysis
|
[PMID: 27352042] |
| HEK293 | IC50 |
2.2 μM
Compound: 1b
|
Antagonist activity at rat TRPV3 overexpressed in HEK293 cells assessed as inhibition of thymol-induced increase in intracellular Ca2+ levels preincubated for 5 mins prior to thymol-stimulation by Fluo-4AM dye-based spectrofluorometry
Antagonist activity at rat TRPV3 overexpressed in HEK293 cells assessed as inhibition of thymol-induced increase in intracellular Ca2+ levels preincubated for 5 mins prior to thymol-stimulation by Fluo-4AM dye-based spectrofluorometry
|
[PMID: 27352042] |
| HeLa | IC50 |
>100 μM
Compound: 1b
|
Inhibition of NFkappaB p65 activation (unknown origin) expressed in human HeLa cells assessed as inhibition of TNFalpha-induced NFkappaB p65 nuclear accumulation pretreated with cells followed by TNFalpha addition by DAPI staining based microscopic analys
Inhibition of NFkappaB p65 activation (unknown origin) expressed in human HeLa cells assessed as inhibition of TNFalpha-induced NFkappaB p65 nuclear accumulation pretreated with cells followed by TNFalpha addition by DAPI staining based microscopic analys
|
[PMID: 27352042] |
| HeLa | IC50 |
>50 μM
Compound: 1b
|
Inhibition of IFNgamma-induced STAT3 activation in human HeLa cells expressing STAT3 (unknown origin) preincubated for 15 mins followed by IFN-gamma addition measured after 6 hrs by luciferase reporter gene assay
Inhibition of IFNgamma-induced STAT3 activation in human HeLa cells expressing STAT3 (unknown origin) preincubated for 15 mins followed by IFN-gamma addition measured after 6 hrs by luciferase reporter gene assay
|
[PMID: 27352042] |
| NIH3T3 | IC50 |
>50 μM
Compound: 1b
|
Inhibition of TNFalpha-induced NFkappaB activation in mouse NIH-3T3 cells expressing NFkappaB (unknown origin) preincubated for 15 mins followed by TNFalpha addition measured after 6 hrs by luciferase reporter gene assay
Inhibition of TNFalpha-induced NFkappaB activation in mouse NIH-3T3 cells expressing NFkappaB (unknown origin) preincubated for 15 mins followed by TNFalpha addition measured after 6 hrs by luciferase reporter gene assay
|
[PMID: 27352042] |
Incensole acetate (100 μM; pre-treatment 4 hours) significantly ameliorates Aβ 25–35-induced cell death, a 48–52% decrease in cell viability at Aβ25–35 is restored to 85–89% upon pre-treatment with IA[1]. Incensole acetate (5-100 μM) pretreatment reverses increase in the mRNA and protein level of Bax, caspase 8, cyto c and decrease in the mRNA and protein level of Bcl2 induced by Aβ 25–35 in hOBNSCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human olfactory bulb neural stem cells
-
Concentration:100 μM
-
Incubation Time:Pre-treatment 4 hours
-
Result:Increased hOBNSCs cell viability induced by Aβ 25-35.
Chemical Information
-
CAS No. 34701-53-6
-
Appearance Liquid (Density: 0.99±0.1 g/cm3)
-
Molecular Weight 348.52
-
Formula C22H36O3
-
Color Colorless to light yellow
-
SMILES
CC([C@@]12C/C=C(C)/CC/C=C(C)/CC[C@H](OC(C)=O)[C@@](O2)(C)CC1)C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 100 mg/mL (286.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.17 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (7.17 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8693 mL | 14.3464 mL | 28.6928 mL | 71.7319 mL |
| 5 mM | 0.5739 mL | 2.8693 mL | 5.7386 mL | 14.3464 mL | |
| 10 mM | 0.2869 mL | 1.4346 mL | 2.8693 mL | 7.1732 mL | |
| 15 mM | 0.1913 mL | 0.9564 mL | 1.9129 mL | 4.7821 mL | |
| 20 mM | 0.1435 mL | 0.7173 mL | 1.4346 mL | 3.5866 mL | |
| 25 mM | 0.1148 mL | 0.5739 mL | 1.1477 mL | 2.8693 mL | |
| 30 mM | 0.0956 mL | 0.4782 mL | 0.9564 mL | 2.3911 mL | |
| 40 mM | 0.0717 mL | 0.3587 mL | 0.7173 mL | 1.7933 mL | |
| 50 mM | 0.0574 mL | 0.2869 mL | 0.5739 mL | 1.4346 mL | |
| 60 mM | 0.0478 mL | 0.2391 mL | 0.4782 mL | 1.1955 mL | |
| 80 mM | 0.0359 mL | 0.1793 mL | 0.3587 mL | 0.8966 mL | |
| 100 mM | 0.0287 mL | 0.1435 mL | 0.2869 mL | 0.7173 mL |
Incensole Acetate Related Classifications
HY-N4098 Related Classifications
Powered by Bioz